Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02717962 · ClinicalTrials.gov registry record · Phase 2
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
A Phase 2 study, sponsored by Kintara Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT02717962 is a Phase 2 study that has completed, run by Kintara Therapeutics. The registered enrollment target is 118 participants.
The verdict
NCT02717962, a Phase 2 study, has completed, sponsored by Kintara Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
The purpose of this phase 2, two arm, biomarker-driven study is to determine if treatment of O-6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastoma with VAL-083 improves overall survival (OS), compared to historical control, in the adjuvant or recurrent setting.
Interventions
- DRUG VAL-083, Dianhydrogalactitol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2017-01-20 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02717962
The ClinicalTrials.gov registry entry for NCT02717962 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kintara Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VAL-083, Dianhydrogalactitol is the first listed.
NCT02717962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02717962 about?
NCT02717962 is a clinical study titled "Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting". The purpose of this phase 2, two arm, biomarker-driven study is to determine if treatment of O-6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastoma with VAL-083 improves overall survival (OS), compared to historical control, in the adjuvant or recurrent setting.
What is the current status of trial NCT02717962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2017-01-20. Estimated completion is 2024-12-30.
What interventions are being tested in trial NCT02717962?
The interventions under investigation include: VAL-083, Dianhydrogalactitol (DRUG).
Who is sponsoring clinical trial NCT02717962?
This trial is sponsored by Kintara Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.